Disulfidptosis: a new target for metabolic cancer therapy

Altered metabolism is a hallmark of cancer and presents a vulnerability that can be exploited in cancer treatment. Regulated cell death (RCD) plays a crucial role in cancer metabolic therapy. A recent study has identified a new metabolic-related RCD known as disulfidptosis. Preclinical findings sugg...

Descripción completa

Detalles Bibliográficos
Autores principales: Zheng, Peijie, Zhou, Chuntao, Ding, Yuemin, Duan, Shiwei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Commentary
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10134647/
https://www.ncbi.nlm.nih.gov/pubmed/37101248
http://dx.doi.org/10.1186/s13046-023-02675-4
_version_ 1785031804669919232
author Zheng, Peijie
Zhou, Chuntao
Ding, Yuemin
Duan, Shiwei
author_facet Zheng, Peijie
Zhou, Chuntao
Ding, Yuemin
Duan, Shiwei
author_sort Zheng, Peijie
collection PubMed
description Altered metabolism is a hallmark of cancer and presents a vulnerability that can be exploited in cancer treatment. Regulated cell death (RCD) plays a crucial role in cancer metabolic therapy. A recent study has identified a new metabolic-related RCD known as disulfidptosis. Preclinical findings suggest that metabolic therapy using glucose transporter (GLUT) inhibitors can trigger disulfidptosis and inhibit cancer growth. In this review, we summarize the specific mechanisms underlying disulfidptosis and outline potential future research directions. We also discuss the challenges that may arise in the clinical translation of disulfidptosis research. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s13046-023-02675-4.
format Online
Article
Text
id pubmed-10134647
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-101346472023-04-28 Disulfidptosis: a new target for metabolic cancer therapy Zheng, Peijie Zhou, Chuntao Ding, Yuemin Duan, Shiwei J Exp Clin Cancer Res Commentary Altered metabolism is a hallmark of cancer and presents a vulnerability that can be exploited in cancer treatment. Regulated cell death (RCD) plays a crucial role in cancer metabolic therapy. A recent study has identified a new metabolic-related RCD known as disulfidptosis. Preclinical findings suggest that metabolic therapy using glucose transporter (GLUT) inhibitors can trigger disulfidptosis and inhibit cancer growth. In this review, we summarize the specific mechanisms underlying disulfidptosis and outline potential future research directions. We also discuss the challenges that may arise in the clinical translation of disulfidptosis research. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s13046-023-02675-4. BioMed Central 2023-04-27 /pmc/articles/PMC10134647/ /pubmed/37101248 http://dx.doi.org/10.1186/s13046-023-02675-4 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Commentary
Zheng, Peijie
Zhou, Chuntao
Ding, Yuemin
Duan, Shiwei
Disulfidptosis: a new target for metabolic cancer therapy
title Disulfidptosis: a new target for metabolic cancer therapy
title_full Disulfidptosis: a new target for metabolic cancer therapy
title_fullStr Disulfidptosis: a new target for metabolic cancer therapy
title_full_unstemmed Disulfidptosis: a new target for metabolic cancer therapy
title_short Disulfidptosis: a new target for metabolic cancer therapy
title_sort disulfidptosis: a new target for metabolic cancer therapy
topic Commentary
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10134647/
https://www.ncbi.nlm.nih.gov/pubmed/37101248
http://dx.doi.org/10.1186/s13046-023-02675-4
work_keys_str_mv AT zhengpeijie disulfidptosisanewtargetformetaboliccancertherapy
AT zhouchuntao disulfidptosisanewtargetformetaboliccancertherapy
AT dingyuemin disulfidptosisanewtargetformetaboliccancertherapy
AT duanshiwei disulfidptosisanewtargetformetaboliccancertherapy

Ejemplares similares